Optimising chemoradiotherapy in anal cancer

Concurrent chemoradiotherapy is the standard treatment for localised squamous-cell carcinoma of the anus. Even though this approach is well established, research efforts are ongoing to optimise this therapeutic option to maximise oncological outcomes, decrease treatment-related toxicity profile, and optimise health-related quality of life. We provide an overview of the available data and the active fields of research in the optimisation of chemoradiotherapy in anal cancer patients. • Concurrent chemoradiation is the standard definitive treatment in localised anal cancer. • Efforts are ongoing to optimise concurrent chemoradiation. • Personalised dose prescription, volume selection and definition and combined modality treatment are being investigated. • Risk stratification, treatment delivery and health-related quality of life are crucial topics of research. • A multidisciplinary approach is cogent.

Authors

Institutions

Publication Details

Journal
ESMO Gastrointestinal Oncology
Published
2025-02-01
DOI
https://doi.org/10.1016/j.esmogo.2025.100141
Citations
1
Primary Topic
Colorectal and Anal Carcinomas
Type
article
Field-Weighted Citation Impact
2.01
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Optimising chemoradiotherapy in anal cancer

Marianne G. Guren, Maria Antonietta Gambacorta, Pierfrancesco Franco, A. Gilbert et al.
1 citations
ESMO Gastrointestinal Oncology
Colorectal and Anal Carcinomas
2.01
article

Optimising chemoradiotherapy in anal cancer

Marianne G. Guren, Maria Antonietta Gambacorta, Pierfrancesco Franco, A. Gilbert, Camilla Kronborg, Letizia Deantonio, R. Muirhead
article en
1 citations

Abstract

Concurrent chemoradiotherapy is the standard treatment for localised squamous-cell carcinoma of the anus. Even though this approach is well established, research efforts are ongoing to optimise this therapeutic option to maximise oncological outcomes, decrease treatment-related toxicity profile, and optimise health-related quality of life. We provide an overview of the available data and the active fields of research in the optimisation of chemoradiotherapy in anal cancer patients. • Concurrent chemoradiation is the standard definitive treatment in localised anal cancer. • Efforts are ongoing to optimise concurrent chemoradiation. • Personalised dose prescription, volume selection and definition and combined modality treatment are being investigated. • Risk stratification, treatment delivery and health-related quality of life are crucial topics of research. • A multidisciplinary approach is cogent.

ESMO Gastrointestinal Oncology
Università Cattolica del Sacro Cuore (IT), Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT), Oslo University Hospital (NO), University of Leeds (GB), University of Oslo (NO), Aarhus University (DK), St James's University Hospital (GB), Aarhus University Hospital (DK), Agostino Gemelli University Polyclinic (IT), Ente Ospedaliero Cantonale (CH), Institute of Oncology Research (CH), Azienda Ospedaliero Universitaria Maggiore della Carita (IT), Azienda Ospedaliera Ospedale Maggiore (IT), Oxford University Hospitals NHS Trust (GB), Università della Svizzera italiana (CH)
Openalex Percentile: Top 19%
Colorectal and Anal Carcinomas
2.01
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.